A certificate whose chromatogram axes do not match its stated method — one year on

Anonymity: a supplier that will not disclose legal name, address, or responsible person is not operating in a way that allows accountability.

Two things before anyone answers the substance.

First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.

Picking up post #14: that is the part I would want checked first.

Documentation quality as a signal: a supplier that reports method identifiers, distinguishes specification from result, and states the counter-ion form is telling you something about systems behind the document. A certificate that is a number and a signature tells you less.

Coming back to post #16, because the follow-up matters more than the original answer.

Patterns that reliably precede a problem: underdosing (less active material than stated, documented by independent testing), mislabelling (wrong compound, wrong strength, or wrong batch on the label), and failure to provide documentation when asked.

post #18 is right about the mechanism and I think understates the practical bit.

Inconsistency across documents: a certificate stating one purity, a website claiming another, and a supplier's verbal representation claiming a third, all on the same product, is a red flag for either incompetence or deception.

Worth separating two things that post #16 runs together.

Pricing patterns: unusually low prices for what are otherwise consistent with market rates might indicate lower quality, stolen goods, or a scam. Unusually high prices without justification raise different flags.

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

post #21 answers the question as asked. The question underneath it is different.

Inability to trace lots: if you ask "where was this synthesised, by whom, under what conditions" and cannot get a clear answer, that is a red flag. Traceability is not glamorous but it is foundational.

Coming back to post #21, because the follow-up matters more than the original answer.

Unresponsiveness: a supplier that does not reply to reasonable requests for documentation or clarification is showing you something about how they operate.

Safety documentation absent: a supplier that cannot provide information about sterility testing, endotoxin testing, or safety documentation when asked is raising flags.

Worth separating two things that post #21 runs together.

Evasion when asked: if a supplier does not clarify when asked specifically for method details, counter-ion form, or batch origin, that itself is a red flag worth documenting.

post #25 is right about the mechanism and I think understates the practical bit.

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

Exaggerated claims without documentation: every compound has limits. No peptide is "100% pure" because purity is measured to finite precision. A supplier claiming implausible perfection without backing evidence is overreaching.

On post #25 — agreed on the reasoning, with one qualification.

Rapid supplier turnover: a supplier that changes corporate structure, domain name, or contact repeatedly in short time windows raises suspicion about stability and legitimacy.

Exaggerated claims without documentation: every compound has limits. No peptide is "100% pure" because purity is measured to finite precision. A supplier claiming implausible perfection without backing evidence is overreaching.